Natalie McClure, SVP, Product Development at Adamas Pharmaceuticals Inc (ADMS), sold 2,000 shares at $16.87 ($34K) on 2015-02-05, disclosed to the SEC on 2015-02-06.
Scheduled sale ($34k) by SVP, Product Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| ADMS | SELL | 2015-05-07 | $35K | — | Filing → |
| ADMS | SELL | 2015-04-07 | $35K | — | Filing → |
| ADMS | SELL | 2015-03-09 | $34K | — | Filing → |